Bringing the Oncology Community Together

Dr. Bradley Discusses Moxetumomab Pasudotox

Edward Bradley, MD
Published Online: Tuesday, July 30, 2013
Edward Bradley, MD, Senior Vice President, Head, Innovative Medicines unit (iMED), MedImmune (the global biologics research and development arm of AstraZeneca), discusses the development of moxetumomab pasudotox.

Moxetumomab pasudotox is a monoclonal antibody made up of an antibody directed at CD22 and Pseudomonas exotoxin. The agent binds to CD22 on the surface of the tumor cell and is incorporated into the cell before the Pseudomonas exotoxin metabolizes, is released, and kills the cell.

In a phase I trial, patients with hairy cell leukemia who had failed previous therapy saw over 90% response rate, with over half being complete responses. Bradley said that the durability of the responses was most striking and that moxetumomab pasudotox was well-tolerated.

Related Articles
Hitting the Target: How Druker’s Persistence Helped Launch a New Mode of Attack
Take a prognosis of three years, multiply it by 10, and what do you get? A staggering improvement in the survival of patients with chronic myeloid leukemia (CML), and a crucial steppingstone on the road to the targeted treatment of cancer.
MSK's CAR Trials Halted Temporarily Amid Safety Review
Five early-phase clinical trials exploring chimeric antigen receptor (CAR) T-cell therapy have been suspended temporarily in response to the deaths of 2 patients with adult B-cell acute lymphoblastic leukemia
Defining and Predicting Response to HMAs in MDS
In this segment, panelists discuss the lack of a clear connection between response to hypomethylating agents and molecular genetics as well as the larger role for cytogenetic assessment of response for patients with myelodysplastic syndrome.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.